After U.S. markets closed for trading yesterday, medical device company Sensus Healthcare Inc. (SRTS:NASDAQ), which manufactures and sells equipment used for carrying out cost-effective, non-invasive, and minimally-invasive superficial radiation therapy (SRT) treatments for oncological and other non-oncological skin conditions, announced financial results for Q2/22 and H1/22 ended June 30, 2022.
Sensus Healthcare reported that during Q2/22 revenues increased by 124% to $12.1 million, compared to $5.4 million in Q2/21. The firm noted that the increase in revenues was driven by higher unit sales, higher services revenue, and lower comps for Q1/21 due to impacts from COVID-19.
The company advised that in Q2/22 it posted a net income of $3.5 million, or $0.21 per diluted share, versus a net loss of $0.3 million, or $0.02 per diluted share in Q2/21.
The firm added that for Q2/22, adjusted EBITDA came in at $4.7 million, compared to adjusted EBITDA of $(0.1) million in the prior year's corresponding quarter.
Sensus indicated that at the end of the latest quarter it held cash and cash equivalents of $33.7 million on its balance sheet and had no outstanding borrowings under its revolving credit line.
The company advised that it expects growth to continue in Q3/22 and affirmed its expectations for profitability in FY/22.
The firm commented on a few recent business activities and stated that in Q2/22 it received orders for ten TransDermal Infusion Systems™ from Hair Enhancement Centers, shipped five units to Asia, and delivered a second SRT System to the College of Veterinary Medicine and Biomedical Sciences at Colorado State University.
The company's Chairman and CEO Joe Sardano commented, "I'm delighted with our continued strong financial performance ... We remain focused on our core dermatology business, building upon the initiatives we put in place during the past two years, leveraging improved reimbursement for superficial radiation therapy to treat non-melanoma skin cancers and keloids, offering an attractive fair value lease program to physician customers, maintaining an active presence at dermatology conferences and trade shows and, most recently, implementing a new marketing campaign that includes both digital and television platforms."
Sardano continued, "More than half our customers have purchased premium-featured SRT-100 Vision™ systems under a leasing agreement, while approximately 80% of systems coming off a one-year warranty continue with a service agreement, providing a significant source of recurring revenue."
"The launch of our TransDermal Infusion System™ is going very well and generating significant interest among potential customers who recognize its ability to eliminate injections. The system permits many procedures to be less painful for patients, and interest is particularly high for aesthetic facial procedures, hair growth, and hyperhidrosis treatments," Sardano added.
The firm advised that revenues in H1/22 were up 164% year-over-year at $22.4 million, compared to $8.5 million in H1/21. Sensus attributed the increase primarily to higher unit sales, which in turn helped generate additional service revenue from installed units.
The company stated for H1/22 it recorded a net income of $19.6 million, or $1.17 per diluted share, versus a net loss of $1.4 million, or a loss of $0.08 per share in H1/21. The firm indicated that in Q1/22 it registered a $12.8 million gain from the sale of a non-core asset.
Sensus Healthcare is a medical device company based in Boca Raton, Fla. that manufactures and sells radiation therapy devices to healthcare providers worldwide. The firm's devices are used to conduct non-invasive and minimally invasive procedures for both oncological and non-oncological conditions. The company's products employ low-energy X-ray technology called superficial radiation therapy (SRT) to treat non-melanoma skin cancers and keloids. The firm's medical device products include its needleless TransDermal Infusion System™ and several aesthetic lasers including its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems.
Sensus Healthcare Inc. began the day with a market cap of around $185.63 million with approximately 16.68 million shares outstanding and a short interest of about 2.37%. SRTS shares opened 13% higher today at $12.58 (+$1.45, +13.03%) over yesterday's $11.13 closing price and reached a new 52-week high price this afternoon of $14.82. The stock has traded today between $12.0252 and $14.82 per share and is currently trading at $14.68 (+$3.55, +31.90%).
| Want to be the first to know about interesting Medical Devices investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Disclosure:
1) Stephen Hytha wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
